The appointment of Dr. Banerjee culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmunity and cell therapy that includes the following recent additions: ...

Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

The Switzerland-based firm's MosaiQ AiPlex Connective Tissue Diseases (CTDplus) assay is used to aid the diagnosis of autoimmune diseases.

Now, a new study suggests that vivid hallucinations—both during sleep and while awake—could point to an underlying autoimmune disorder. Published in the journal eClinicalMedicine, a recent study found ...

Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...

Cabaletta has been evaluating the CAR-T, called resecabtagene autoleucel or rese-cel , across six so-called RESET studies ...